Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update

Keros Therapeutics, Inc. (NASDAQ:KROS) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 4,260,000 shares, an increase of 6.0% from the January 15th total of 4,020,000 shares. Based on an average daily trading volume, of 1,500,000 shares, the short-interest ratio is currently 2.8 days.

Keros Therapeutics Price Performance

KROS stock traded up $0.17 during trading on Monday, reaching $10.32. 966,902 shares of the company were exchanged, compared to its average volume of 2,180,866. The company has a 50-day moving average of $16.91 and a two-hundred day moving average of $42.00. The company has a market capitalization of $418.06 million, a price-to-earnings ratio of -1.98 and a beta of 1.39. Keros Therapeutics has a twelve month low of $9.77 and a twelve month high of $73.00.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on KROS. BTIG Research lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Oppenheimer cut their price objective on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday, January 16th. Guggenheim reissued a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Wedbush downgraded shares of Keros Therapeutics from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $47.00 to $15.00 in a report on Friday, January 17th. Finally, Piper Sandler cut their price objective on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a report on Friday, January 17th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $52.56.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV increased its position in Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after acquiring an additional 280 shares during the period. Values First Advisors Inc. acquired a new position in Keros Therapeutics in the 3rd quarter valued at approximately $89,000. AlphaQuest LLC increased its position in Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock valued at $57,000 after acquiring an additional 2,964 shares during the period. Finally, LMR Partners LLP acquired a new position in Keros Therapeutics in the 3rd quarter valued at approximately $213,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.